Proteomedix

Switzerland
Schlieren, Zurich, Switzerland, 8952

Company profile

Proteomedix company profile

Proteomedix (an Onconetix company; NASDAQ:ONCO) is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland.

Business identity

Contact email
[email protected]
Phone number
0041 44 733 40 90
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2010-03-01

Headquarters

Postal code
8952
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
9
Total equity funding
$18.1M
Last funding
Debt Financing / $3.2M / 2021-09-21
Last equity funding
Series Unknown / $5.3M
Investors
8
Lead investors
5
Founders
3
Articles
29
Exited on
2023-12-18

Founders and investors

Founders

Christian BrühlmannRalph SchiessWilhelm Krek

Lead investors

Altos VentureAltos VenturesNew Horizon HealthVenture KickWalter Fischl

Investors

Altos VentureAltos VenturesNew Horizon HealthVenture KickZürcher Kantonal Bank